It is not clear whether OPG is a risk factor or only a risk marker of cardiovascular disease [7, 8]; therefore, further research is needed in this regard, as it could determine whether recombinant OPG can be used in the treatment of JPD. This evidence concerns the gene TNFRSF11B and cardiovascular disorder.